Point-of-care diagnostics for infectious diseases: From methods to devices

C Wang, M Liu, Z Wang, S Li, Y Deng, N He - Nano Today, 2021 - Elsevier
The current widespread of COVID-19 all over the world, which is caused by SARS-CoV-2
virus, has again emphasized the importance of development of point-of-care (POC) …

Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults

KR Steingart, H Sohn, I Schiller… - Cochrane database …, 2013 - cochranelibrary.com
Background Accurate and rapid detection of tuberculosis (TB) and drug resistance are
critical for improving patient care and decreasing the spread of TB. Xpert® MTB/RIF assay …

[HTML][HTML] Cost–effectiveness thresholds: pros and cons

MY Bertram, JA Lauer, K De Joncheere… - Bulletin of the World …, 2016 - ncbi.nlm.nih.gov
Cost–effectiveness analysis is used to compare the costs and outcomes of alternative policy
options. Each resulting cost–effectiveness ratio represents the magnitude of additional …

Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled …

G Theron, L Zijenah, D Chanda, P Clowes, A Rachow… - The Lancet, 2014 - thelancet.com
Summary Background The Xpert MTB/RIF test for tuberculosis is being rolled out in many
countries, but evidence is lacking regarding its implementation outside laboratories, ability to …

Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

SD Lawn, P Mwaba, M Bates, A Piatek… - The Lancet infectious …, 2013 - thelancet.com
Rapid progress has been made in the development of new diagnostic assays for
tuberculosis in recent years. New technologies have been developed and assessed, and …

Initiating antiretroviral therapy for HIV at a patient's first clinic visit: the RapIT randomized controlled trial

S Rosen, M Maskew, MP Fox, C Nyoni… - PLoS …, 2016 - journals.plos.org
Background High rates of patient attrition from care between HIV testing and antiretroviral
therapy (ART) initiation have been documented in sub-Saharan Africa, contributing to …

PCR technologies for point of care testing: progress and perspectives

S Petralia, S Conoci - ACS sensors, 2017 - ACS Publications
Since the Human Genome Project completed in 2000, the sequencing of the first genome,
massive progress has been made by medical science in the early diagnosis and …

Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis

JS Zifodya, JS Kreniske, I Schiller… - Cochrane Database …, 2021 - cochranelibrary.com
Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health
Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and …

Trichomonas vaginalis: Clinical relevance, pathogenicity and diagnosis

T Edwards, P Burke, H Smalley… - Critical reviews in …, 2016 - Taylor & Francis
Trichomonas vaginalis is the etiological agent of trichomoniasis, the most prevalent non-viral
sexually transmitted disease worldwide. Trichomoniasis is a widespread, global health …

Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation

NA Menzies, T Cohen, HH Lin, M Murray… - PLoS …, 2012 - journals.plos.org
Background The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and
rifampicin resistance. The World Health Organization recommends Xpert for initial diagnosis …